Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol.

A. Bron, Philippe Denis, J. Nordmann, J. Rouland, E. Sellem, Marianne Johansson
{"title":"Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol.","authors":"A. Bron, Philippe Denis, J. Nordmann, J. Rouland, E. Sellem, Marianne Johansson","doi":"10.1034/J.1600-0420.2001.790316.X","DOIUrl":null,"url":null,"abstract":"PURPOSE\nTo evaluate the effect on intraocular pressure (IOP) of switching from timolol to latanoprost or adding latanoprost to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol.\n\n\nMETHODS\nThis was a 6-week, double-masked, randomised multi-centre study. 53 patients with primary open angle glaucoma, capsular glaucoma, or ocular hypertension with an IOP of at least 21 mmHg on current therapy were recruited. After a run-in period of at least 2 weeks on timolol, 5 mg/ml twice daily, patients were randomised to one of three groups. One group continued on timolol, one switched from timolol to latanoprost, 50 microg/ml once daily, and a third group received latanoprost in addition to timolol. The efficacy was evaluated by comparing IOP at 9 AM at baseline and after 6 weeks of treatment.\n\n\nRESULTS\nIOP at baseline and after 6 weeks of treatment (mean +/- SEM) were 24.2 +/- 0.9 and 23.8 +/- 1.0 mmHg (n = 16) for patients continuing on timolol, 26.3 +/- 1.2 and 19.6 +/- 1.1 mmHg (n = 17) for patients switching to latanoprost, and 23.2 +/- 1.0 and 17.5 +/- 0.8 mmHg (n = 17) for patients with combined treatment. Adding latanoprost to timolol reduced IOP with 5.9 +/- 0.9 mmHg (p < 0.001) and switching from timolol to latanoprost reduced IOP with 5.0 +/- 0.9 mmHg (p < 0.001), which caused in each group a significant IOP reduction of about 25%.\n\n\nCONCLUSIONS\nThe effect of latanoprost was additive to that of timolol, and a good effect on IOP reduction was also achieved by switching from timolol to latanoprost, suggesting that a switch in many patients is an effective alternative to combination treatment.","PeriodicalId":7152,"journal":{"name":"Acta ophthalmologica Scandinavica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2001-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"21","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta ophthalmologica Scandinavica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1034/J.1600-0420.2001.790316.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 21

Abstract

PURPOSE To evaluate the effect on intraocular pressure (IOP) of switching from timolol to latanoprost or adding latanoprost to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol. METHODS This was a 6-week, double-masked, randomised multi-centre study. 53 patients with primary open angle glaucoma, capsular glaucoma, or ocular hypertension with an IOP of at least 21 mmHg on current therapy were recruited. After a run-in period of at least 2 weeks on timolol, 5 mg/ml twice daily, patients were randomised to one of three groups. One group continued on timolol, one switched from timolol to latanoprost, 50 microg/ml once daily, and a third group received latanoprost in addition to timolol. The efficacy was evaluated by comparing IOP at 9 AM at baseline and after 6 weeks of treatment. RESULTS IOP at baseline and after 6 weeks of treatment (mean +/- SEM) were 24.2 +/- 0.9 and 23.8 +/- 1.0 mmHg (n = 16) for patients continuing on timolol, 26.3 +/- 1.2 and 19.6 +/- 1.1 mmHg (n = 17) for patients switching to latanoprost, and 23.2 +/- 1.0 and 17.5 +/- 0.8 mmHg (n = 17) for patients with combined treatment. Adding latanoprost to timolol reduced IOP with 5.9 +/- 0.9 mmHg (p < 0.001) and switching from timolol to latanoprost reduced IOP with 5.0 +/- 0.9 mmHg (p < 0.001), which caused in each group a significant IOP reduction of about 25%. CONCLUSIONS The effect of latanoprost was additive to that of timolol, and a good effect on IOP reduction was also achieved by switching from timolol to latanoprost, suggesting that a switch in many patients is an effective alternative to combination treatment.
拉坦前列素对替马洛尔控制不足患者的附加性降眼压作用。
目的探讨替马洛尔不能有效控制眼压的开角型青光眼或高眼压患者,由替马洛尔改用拉坦前列素或拉坦前列素加替马洛尔对眼压的影响。方法:这是一项为期6周、双盲、随机多中心的研究。53例原发性开角型青光眼、荚膜型青光眼或高眼压患者接受当前治疗,IOP至少为21 mmHg。经过至少2周的替莫洛尔(5mg /ml,每日两次)磨合期后,患者被随机分为三组之一。一组继续使用替洛尔,一组从替洛尔改为拉坦前列素,50微克/毫升,每日一次,第三组在使用替洛尔的同时使用拉坦前列素。通过比较治疗6周后上午9点和基线时的IOP来评估疗效。结果基线时和治疗6周后,继续使用替洛尔的患者(平均+/- SEM)为24.2 +/- 0.9和23.8 +/- 1.0 mmHg (n = 16),改用拉坦前列素的患者为26.3 +/- 1.2和19.6 +/- 1.1 mmHg (n = 17),联合治疗的患者为23.2 +/- 1.0和17.5 +/- 0.8 mmHg (n = 17)。拉坦前列素加替莫洛尔可使IOP降低5.9 +/- 0.9 mmHg (p < 0.001),而由替莫洛尔改用拉坦前列素可使IOP降低5.0 +/- 0.9 mmHg (p < 0.001),两组IOP均显著降低约25%。结论拉坦前列素与替马洛尔的作用是叠加性的,由替马洛尔转为拉坦前列素对降低IOP也有很好的效果,提示许多患者改用拉坦前列素是联合治疗的一种有效选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信